Last reviewed · How we verify
Vascular filling
Vascular filling is a Small molecule drug developed by Assistance Publique - Hôpitaux de Paris. It is currently in Phase 3 development for Vascular insufficiency or hypoperfusion states (specific indication unclear from available information). Also known as: Fluid expansion, Sodium Chloride NaCl 0.9%..
Vascular filling is a procedure or therapeutic approach designed to restore or enhance vascular volume and perfusion in compromised vascular beds.
Vascular filling is a procedure or therapeutic approach designed to restore or enhance vascular volume and perfusion in compromised vascular beds. Used for Vascular insufficiency or hypoperfusion states (specific indication unclear from available information).
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Cardiovascular Phase 3 risk
-2.0pp
Modern cardiovascular outcome trials are large + long; many fail to beat aggressive standard-of-care.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Vascular filling |
|---|---|
| Also known as | Fluid expansion, Sodium Chloride NaCl 0.9%. |
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
This appears to be a clinical intervention rather than a traditional pharmacological agent, likely involving fluid or blood product administration to restore intravascular volume and improve tissue perfusion. The exact mechanism depends on the specific formulation or approach being evaluated in the phase 3 trial.
Approved indications
- Vascular insufficiency or hypoperfusion states (specific indication unclear from available information)
Common side effects
Key clinical trials
- Uncalibrated Pulse Contour to Assess Fluid Responsiveness in Off Pump Cardiac Surgery
- The Effect of Near-infrared Spectroscopy on the Success of Peripheral Venous Access (NA)
- The Value of Measuring Retinal Vascular Density by Optical Coherence Tomography-Angiography (OCT-A) in Patients With Microvascular Angina Confirmed by Myocardial Microcirculatory Resistance Index (MRI).
- Decrease of Post-operative Complications by SCVO2 Monitoring an Optimisation of Cardiac Flow (NA)
- Evaluation of the Venous Excess Ultrasound Score (VExUS) After Circulating Volume Modification in Children.
- Comparative Study Between Sclerosing Agents Used in Treatment of Vascular Malformation (NA)
- AAA-SHAPE Pivotal Trial: Abdominal Aortic Aneurysm Sac Healing and Prevention of Expansion (NA)
- Efficacy of Intraoperative Use of 20% Albumin Combined With Ringer Lactate Versus Ringer Lactate During Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vascular filling CI brief — competitive landscape report
- Vascular filling updates RSS · CI watch RSS
- Assistance Publique - Hôpitaux de Paris portfolio CI
Frequently asked questions about Vascular filling
What is Vascular filling?
How does Vascular filling work?
What is Vascular filling used for?
Who makes Vascular filling?
Is Vascular filling also known as anything else?
What development phase is Vascular filling in?
Related
- Manufacturer: Assistance Publique - Hôpitaux de Paris — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Vascular insufficiency or hypoperfusion states (specific indication unclear from available information)
- Also known as: Fluid expansion, Sodium Chloride NaCl 0.9%.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing